Mayo Clinic
HemOnc Fellow in Mayo Clinic in Florida- Interested in prostate cancer, immunotherapy and NETs.
Talks (65)
Air Time: 355:32:47
Capivasertib in mBC
Dec 20
Ev Pembro FDA approval
Dec 17
Belzutifan FDA approval RCC
Dec 15
Triplet therapy in mRCC
Dec 01
Pembro in Cholangiocarcinomq
Nov 30
Ultraprocessed food and risk of cancer
Nov 30
Pembro plus Chemo GEJ cancers
Nov 28
Fruquintinib in mCRC
Nov 28
Ropotrectinib FDA APPROVAL
Nov 28
FDA Approval for Enza in nmCSPS with BCR
Nov 23
Erdafitinib Vs Chemo in mUC
Nov 23
Pembrolizumab in RCC
Nov 02
Erdafitinib or Pembro in FGFR mUC
Oct 30
THOR Cohort 1: Erda in mUC
Oct 30
Nivolumab plus Gem-Cis in Advanced UC
Oct 28
Erdafitinib in NMIBC
Oct 23
LEAP 011- Lenvatinib and Pembro in mUC
Oct 01
Gut Microbiota and Immunotherapy
Sep 29
Exercise and Lynch syndrome
Sep 29
Thromboprophylaxis in cancer patients
Sep 27
Primary VTE prophylaxis in Cancer pts
Sep 27
Rogarafenib+Nivo FOLFOX in E&GEJ cancers
Sep 25
Agnostic approvals in oncology 2
Sep 16
Agnostic Drug approvals in oncology
Sep 16
Steroids and immunotherapy response
Aug 30
Divarasib in KRAS G12C mutant tumors
Aug 30
PROSPECT TRIAL-NEOADJUVANT FOLFOX
Aug 29
DESTINY GASTRIC 02 trial
Aug 24
ATORVASTATIN and Anthracyclines
Aug 24
PEMBRO LEN In Non clear cell RCC
Aug 16
EV+ Pembro in mUC 2
Jul 24
JAVELIN BLADDER TRIAL 2
Jul 13
JAVELIN BLADDER TRIAL
Jul 13
Magnitude Trial: Niraparib in mCRPC 2
Jun 26
MAGNITUDE TRIAL: Niraparib inmCRPC
Jun 26
SWOG S1826: Nivo+ AVD in cHL
Jun 21
FDA approval for Glofitamab in R/R DLBCL
Jun 17
Duration of ICI in Advanced NSCLC
Jun 15
Luspatercept in Low risk MDS
Jun 14
